RXRX stock forecast, quote, news & analysis
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company... Show more
Recursion Pharmaceuticals (RXRX) Stock Analysis: Pipeline Progress Amid Cash Burn Pressures
Key Takeaways
- Recursion Pharmaceuticals reported Q1 2026 revenue of $6.47 million, missing estimates, with a net loss of $117.5 million but cash reserves of $665.2 million extending runway into early 2028.
- Clinical advancements include positive early data for REC-1245 (no dose-limiting toxicities) and REC-4881 (polyp reductions in familial adenomatous polyposis), alongside first dosing in REC-4539.
- Analyst consensus leans overweight with an average price target of $6.64, implying over 100% upside from recent levels around $3.05.
- Partnership milestones with Sanofi, Roche, and Genentech have delivered over $500 million in inflows, supporting a diversified pipeline.
- Stock trades near 52-week lows amid biotech sector volatility, with elevated short interest adding potential for sentiment shifts.
Current Market Snapshot
In recent trading sessions, Recursion Pharmaceuticals (RXRX) stock has hovered near the lower end of its 52-week range, reflecting broader pressures in the biotech sector alongside company-specific financial results. The shares have experienced volatility tied to clinical updates and earnings, trading significantly below analyst price targets. Elevated trading volumes signal active investor interest, while a robust cash position provides stability amid ongoing R&D investments. Sentiment balances optimism over AI-driven drug discovery progress against concerns over revenue generation and path to profitability, positioning RXRX as a high-risk, high-reward play in the TechBio space.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of over 25 top-performing AI trading bots from a library of 351, tailored for copy trading across stocks, ETFs, and crypto. These bots adapt to current market conditions, featuring diverse strategies such as real-time signal agents with no minimum balance requirements, virtual agents offering risk management and customizable portfolios, and brokerage agents leveraging Tickeron’s accounts. They operate on short timeframes like 60-minute, 15-minute, and 5-minute charts, suiting various volatility levels from low to high. While specific performance metrics vary by bot, the trending list highlights those demonstrating strong recent results in dynamic environments, trading thousands of tickers including biotech names like RXRX. Investors can explore these tools to potentially enhance trading efficiency—visit the page to review and select bots aligned with your strategy.
Recent Developments Driving RXRX Price Action
Recursion Pharmaceuticals (RXRX), a clinical-stage TechBio company leveraging AI for drug discovery, has seen its stock pressured in recent weeks amid mixed Q1 2026 results and ongoing biotech sector headwinds. On May 6, 2026, the company reported first-quarter revenue of $6.47 million, well below the $15.78 million consensus estimate, primarily due to lower-than-expected milestone payments. Net loss narrowed slightly to $117.5 million from prior periods, with cash, cash equivalents, and restricted cash at $665.2 million as of March 31, 2026—down from $753.9 million at year-end 2025 but sufficient to fund operations into early 2028 without additional financing. Management reaffirmed 2026 operational cash burn below $390 million, underscoring cost discipline after a 35% reduction in expenses last year.
The earnings miss contributed to post-report selling, with shares dropping over 10% in the following sessions amid heightened scrutiny on revenue timelines. However, pipeline catalysts provided counterbalance. Early Phase 1 data for REC-1245, an RBM39-targeted degrader for solid tumors, showed no dose-limiting toxicities (DLTs) across 16 patients and dose-dependent pharmacokinetics, supporting escalation. REC-4881, an oral MEK inhibitor for familial adenomatous polyposis (FAP), demonstrated median polyp burden reductions of 43% at week 13 and 53% at week 25 in Phase 2, prompting FDA discussions for a potential registrational study. Additionally, the first patient was dosed in the Phase 1 trial of REC-4539, targeting cerebral cavernous malformation.
Partnerships bolstered sentiment: Recursion achieved a fifth milestone with Sanofi ($4 million) for a first-in-class oncology program, part of over $500 million in total inflows and 10+ deliverables across collaborations with Sanofi (immunology/oncology), Roche, and Genentech (biology maps from massive iPSC-derived cell datasets). Earlier in April, a board transition was announced, with founder Chris Gibson completing his term in June 2026 but remaining an advisor, signaling continuity under CEO Najat Khan.
Analyst reactions were mixed: Needham reiterated Buy with $8 target (May 7), Morgan Stanley raised to $5.50 from $5 (Equal-Weight, May 14), Bank of America issued Hold (May 13), and JPMorgan cut to $10 from $11 (Overweight, late April). Consensus remains Overweight (3 Buy, 5 Hold from 8 analysts), with average target $6.64 (high $10, low $3), implying substantial upside. Price action reflected this tug-of-war: shares fell ~20% from early May highs around $3.90 to ~$3.05, near 52-week lows, on ~14 million average daily volume amid ~40% short interest. Macro factors like interest rate sensitivity in growth biotechs amplified downside, but clinical proof points and partner validation sustained buying interest.
2026 Outlook and Key Factors to Monitor
As Recursion navigates 2026, focus will center on pipeline derisking and platform validation in a competitive TechBio landscape. Consensus projects full-year revenue around $66-82 million, driven by milestones from Sanofi (development candidates in immunology/oncology), Roche/Genentech (target validation from multi-modal biology maps), and internal programs. EPS estimates hover at -$0.93, with losses persisting amid R&D scaling, though cash efficiency targets under $390 million burn support runway into 2028.
Key themes include REC-4881 registrational path in FAP, REC-1245 expansion data, and Phase 1 readouts for REC-4539/REC-3565 in oncology/neuroscience. Partnerships de-risk development, with opt-ins possible for five programs. Industry trends like AI integration in trials (30-60% faster enrollment via ClinTech) and real-world data from expanded Citeline alliance could accelerate decisions. Risks encompass clinical setbacks, regulatory hurdles for novel modalities (e.g., degraders), funding needs if milestones delay, and competition from peers like Exscientia. Opportunities lie in oncology/rare disease orphan designations, cost synergies from Recursion OS 2.0, and macro biotech recovery. Investors should track Q2 earnings (August 2026), milestone announcements, and short interest dynamics for sentiment inflection.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
RXRX's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for RXRX turned positive on June 25, 2026. Looking at past instances where RXRX's MACD turned positive, the stock continued to rise in of 51 cases over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on June 24, 2026. You may want to consider a long position or call options on RXRX as a result. In of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
RXRX moved above its 50-day moving average on June 25, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where RXRX advanced for three days, in of 251 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The 10-day RSI Indicator for RXRX moved out of overbought territory on June 02, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator moved out of overbought territory. In of the 26 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The 10-day moving average for RXRX crossed bearishly below the 50-day moving average on June 15, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RXRX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
RXRX broke above its upper Bollinger Band on June 26, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for RXRX entered a downward trend on May 29, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.647) is normal, around the industry mean (20.978). P/E Ratio (0.000) is within average values for comparable stocks, (36.006). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.690). RXRX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (23.148) is also within normal values, averaging (366.957).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. RXRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RXRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology